dpp-4 inhibitor and glp-1 receptor agonist combination not recommended ada Neuroprotection by dipeptidyl-peptidase-4 inhibitors glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer's disease Role of DPP-4 Inhibitors in

It continues to be a major cause of illness, disability, and death at all ages (211)

doi:10.1111/dom.12165

[1] Healthcare providers may need to adjust the dosages of these concomitant medications to mitigate the risk of hypoglycemia

For all other indications, physicians must prescribe these medications off-label. To understand current physician prescribing practices of off-label GLP-1RA uses, Cure, a healthcare innovation ecosystem in New York City, in conjunction with the Deerfield Institute, a division of Deerfield Management Company, an affiliate of Cure, surveyed 122 physicians across the specialties of gastroenterology, addiction medicine, cardiology, neurology and orthopedics